Skip to main content
Terug
Watch Compare

Cyclerion Therapeutics, Inc.

Datakwaliteit: 100%
CYCN
Nasdaq Manufacturing Chemicals
€ 3,10
▲ € 0,21 (7,27%)
Marktkapitalisatie: 13,42 M
Prijs
€ 3,10
Marktkapitalisatie
13,42 M
Dagbereik
€ 2,85 — € 3,75
52-Weeksbereik
€ 1,03 — € 8,48
Volume
2.055.678
Openen € 2,89
50D / 200D Gem.
€ 1,64
89,36% above
50D / 200D Gem.
€ 2,08
49,33% above

Quick Summary

Belangrijkste Punten

Revenue declined -14,83% annually over 5 years
Negative free cash flow of -3,31 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 18,53%

Groei

Revenue Growth (5Y)
-14,83%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)3,70%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-38,97%
Boven sectorgemiddelde (-53,41%)
ROIC-43,39%
Net Margin-170,11%
Op. Margin-239,78%

Veiligheid

Debt / Equity
N/A
Current Ratio5,78
Interest CoverageN/A

Waardering

PE (TTM)
-3,80
Onder sectorgemiddelde (-1,48)
P/B Ratio1,41
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -3,8 -1,5
P/B 1,4 1,6
ROE % -39,0 -53,4
Net Margin % -170,1 -41,5
Rev Growth 5Y % -14,8 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 3,70% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -14,83% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,07 M Net Income (TTM) -3,53 M
ROE -38,97% ROA -35,66%
Gross Margin N/A Operating Margin -239,78%
Net Margin -170,11% Free Cash Flow (TTM) -3,31 M
ROIC -43,39% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,78
Interest Coverage N/A Asset Turnover 0,21
Working Capital 4,19 M Tangible Book Value 9,54 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,80 Forward P/E N/A
P/B Ratio 1,41 P/S Ratio 6,47
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24,69%
Market Cap 13,42 M Enterprise Value 8,86 M
Per Share
EPS (Diluted TTM) -1,11 Revenue / Share 0,48
FCF / Share -0,77 OCF / Share -0,77
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 93,93%
SBC-Adj. FCF -3,80 M Growth Momentum 18,53

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,07 M 2,00 M 0,0 1,63 M 3,94 M
Net Income -3,53 M -3,06 M -5,26 M 44,10 M -51,65 M
EPS (Diluted) -1,11 -1,21 -2,25 -1,01 —
Gross Profit — — — — —
Operating Income -4,97 M -3,63 M -12,95 M -44,37 M -55,20 M
EBITDA — — — — —
R&D Expenses 959.000,0 286.000,0 1,52 M 31,49 M 37,64 M
SG&A Expenses — — — — —
D&A — — 0,0 65.000,0 472.000,0
Interest Expense — — — — —
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9,99 M 9,58 M 13,37 M 18,08 M 59,33 M
Total Liabilities — — — — —
Shareholders' Equity 9,09 M 8,85 M 11,29 M 10,45 M 48,25 M
Total Debt — — — 3,50 M 3,50 M
Cash & Equivalents 3,24 M 3,23 M 7,57 M 13,38 M 53,96 M
Current Assets 4,64 M 4,23 M 8,02 M 14,82 M 55,46 M
Current Liabilities 900.000,0 725.000,0 2,09 M 7,63 M 11,09 M